NCT03474133Unknown2 期
Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2019年5月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Continuous complete response (CCR) rate
研究概览
简要总结
This study evaluate possibility of brentuximab vedotin, administered after first treatment failure (no response or relapse after I line therapy) of Hodgkin's lymphoma, to induce durable response or cure without autologous stem cell transplantation.
详细描述
Brentuximab vedotin (BV) can induce durable response or cure in some patients with relapsed or refractory Hodgkin's lymphoma (RR HL) after autologous stem cell transplantation (ASCT) failure. It is expecting that BV alone administered earlier (after first treatment failure, without any additional treatment) can cure some RR HL patients and spare them from ASCT-associated risks and toxicity. Therefore in this study full course of BV which confirmed its curative potential in post-ASCT setting will be applicated to the potentially transplant-eligible RR HL patients immediately after first treatment failure, with a aim to assess curative potential of BV in this setting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients 18 years or older
- •Voluntary written informed consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- •Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse.
- •Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to practice effective barrier contraception during the entire study period and through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse.
- •Patients must have a diagnosis of a morphologically confirmed cluster of differentiation antigen 30 {CD30)-positive classical Hodgkin's lymphoma with primary refractory course or relapse after adequate first-line chemotherapy (with morphologically confirmation of vital tumor)
- •PET-positive measurable disease (at least one lesion with Deauville score of >3 and at >1.5 cm on CT scan)
- •Performance status Eastern Cooperative Oncology Group (ECOG) <3
- •Patients potentially eligible for subsequent ASCT according treating physician decision
- •Clinical laboratory values as specified below within 7 days before the first dose of study drug:
- •Absolute neutrophil count ≥ 1,500/µL unless there is known hematologic/solid tumor marrow involvement
- •Platelet count ≥ 75,000/ µL unless there is known marrow involvement of the disease
- •Total bilirubin must be < 1.5 x the upper limit of the normal (ULN) unless the elevation is known to be due to Gilbert syndrome.
- •ALT or aspartate aminotransferase (AST) must be < 3 x the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of HL tumor in liver.
- •Serum creatinine must be < 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance > 40 mL/minute.
- •Hemoglobin must be ≥ 8g/dL.
排除标准
- •More than one line of chemotherapy due to Classical Hodgkin's lymphoma (any salvage treatment)
- •Previous treatment with brentuximab vedotin
- •Female patient who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period
- •Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol.
- •Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
- •Symptomatic neurologic disease compromising normal activities of daily living or requiring medications
- •Any sensory or motor peripheral neuropathy greater than or equal to Grade 2
- •Known history of any of the following cardiovascular conditions
- •Myocardial infarction within 2 years of enrollment
- •New York Heart Association (NYHA) Class III or IV heart failure (see appendix #1)
- •Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- •Recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50%
- •Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first study drug dose
- •Patients that have received other investigational agents within at least 5 half-lives of last dose of that prior treatment
- •Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin.
- •Known human immunodeficiency virus (HIV) positive
- •Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
- •Diagnosed or treated for another malignancy. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
研究组 & 干预措施
Brentuximab
Experimental
Brentuximab vedotin 1,8 mg/kg, every 21 days, up to 16 cycles
干预措施: Brentuximab Vedotin (Drug)
结局指标
主要结局
Continuous complete response (CCR) rate
时间窗: 3 years
Rate of complete responses lasting without further treatment at least 3 years after initiation of BV therapy
次要结局
- Incidence AE according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 [Safety](1 year)
- Additional therapy-free survival (ATFS)(3 years)
- Overall survival(3 year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin LymphomaNCT01393717City of Hope Medical Center57
终止
2 期
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaHodgkin LymphomaPeripheral T Cell LymphomaAnaplastic Large Cell LymphomaNCT03947255Seagen Inc.12
进行中（未招募）
1 期
A trial to improve disease control after an allogeneic stem cell transplantation for relapsed or refractory classical Hodgkin lymphoma with consolidation therapy by Brentuximab VedotiEUCTR2018-000873-59-DEniversity of Cologne21
已完成
2 期
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDHodgkin LymphomaNCT02298283The Lymphoma Academic Research Organisation40
进行中（未招募）
2 期
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNCT01703949University of Washington28